Chen Li-yan, Yang Bao-shan, Ma Ying-ji, Bi Man-ru, Gao Feng
Department of Infectious Diseases, First Clinical Hospital, Harbin Medical University, Harbin 150001, China.
Zhonghua Gan Zang Bing Za Zhi. 2005 Mar;13(3):209-12.
To investigate the protective effect of stronger neo-minophagen C (SNMC) on fulminant liver failure (FLF).
D-Gal N and LPS were injected once into the abdominal cavity of rats to establish an experimental model of FLF. The level of plasma ALT, Alb, TBil, TNFalpha, NO, ET-1, IL-6 and liver histopathology of the rats were examined.
In the D-Gal N and LPS model of FLF, there was an obvious decline of plasma TNFalpha (F = 52.84), NO (F = 15.81), ET-1 (F = 15.68), IL-6 (F = 15.32) and there was less hepatic tissue damage in SNMC-treated groups using different doses (high dose, medium dose, low dose) and at different times (pre-protection, simultaneous protection, post-protection) compared with those not treated with SNMC. These results indicated that SNMC could be used to treat FLF. It was better to use a low dose of SNMC and use it at the same time as inducing the FLF. There were no differences in the results of those treated with SNMC of different dosages and treated at different times.
SNMC can decrease the mortality of FLF by preventing hepatocyte apoptosis induced by D-Gal N and LPS and inhibit liver inflammation caused by all kinds of factors.
探讨强力新C(SNMC)对暴发性肝衰竭(FLF)的保护作用。
一次性腹腔注射D-氨基半乳糖(D-Gal N)和脂多糖(LPS)建立大鼠FLF实验模型,检测大鼠血浆丙氨酸氨基转移酶(ALT)、白蛋白(Alb)、总胆红素(TBil)、肿瘤坏死因子α(TNFα)、一氧化氮(NO)、内皮素-1(ET-1)、白细胞介素-6(IL-6)水平及肝脏组织病理学变化。
在D-Gal N和LPS诱导的FLF模型中,血浆TNFα(F = 52.84)、NO(F = 15.81)、ET-1(F = 15.68)、IL-6(F = 15.32)水平明显下降,不同剂量(高剂量、中剂量、低剂量)和不同时间(预保护、同时保护、后保护)给予SNMC治疗的组与未给予SNMC治疗的组相比,肝组织损伤较轻。这些结果表明SNMC可用于治疗FLF。低剂量SNMC并在诱导FLF的同时使用效果更佳。不同剂量和不同时间给予SNMC治疗的结果无差异。
SNMC可通过防止D-Gal N和LPS诱导的肝细胞凋亡降低FLF的死亡率,并抑制各种因素引起的肝脏炎症。